X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1634) 1634
index medicus (1565) 1565
male (882) 882
female (874) 874
middle aged (610) 610
catheter-related infections - microbiology (553) 553
catheter-related infections - drug therapy (525) 525
aged (511) 511
adult (485) 485
infectious diseases (468) 468
catheterization, central venous - adverse effects (426) 426
anti-bacterial agents - therapeutic use (421) 421
risk factors (406) 406
catheter-related infections - prevention & control (373) 373
prevention (336) 336
catheter-related infections - epidemiology (335) 335
microbiology (319) 319
infections (316) 316
health aspects (314) 314
bacteremia (301) 301
retrospective studies (299) 299
catheters (293) 293
treatment outcome (293) 293
central venous catheters (262) 262
catheters, indwelling - adverse effects (254) 254
child (251) 251
catheter-related infections - etiology (249) 249
infection (244) 244
catheter-related infections (238) 238
adolescent (236) 236
aged, 80 and over (234) 234
bacteremia - drug therapy (220) 220
bacteremia - microbiology (219) 219
catheter-related infections - diagnosis (211) 211
management (205) 205
blood-stream infections (204) 204
complications (197) 197
prospective studies (186) 186
young adult (184) 184
child, preschool (176) 176
pediatrics (175) 175
incidence (172) 172
risk-factors (170) 170
diagnosis (167) 167
antibiotics (166) 166
central venous catheter (166) 166
anti-bacterial agents - administration & dosage (165) 165
urology & nephrology (161) 161
infant (158) 158
pharmacology & pharmacy (156) 156
care and treatment (155) 155
bacteremia - etiology (153) 153
oncology (153) 153
guidelines (151) 151
nosocomial infections (151) 151
mortality (150) 150
microbial sensitivity tests (147) 147
children (142) 142
cancer (140) 140
sepsis (137) 137
bacteremia - epidemiology (135) 135
epidemiology (135) 135
staphylococcal infections - drug therapy (135) 135
time factors (135) 135
catheterization (134) 134
analysis (131) 131
central venous catheters - adverse effects (131) 131
infectious disease (131) 131
research (129) 129
cross infection - microbiology (128) 128
catheterization, central venous - instrumentation (124) 124
catheters, indwelling - microbiology (122) 122
catheter-related bacteremia (120) 120
hematology (120) 120
hemodialysis (120) 120
catheter-related infection (118) 118
biofilms - drug effects (117) 117
blood-stream infection (116) 116
cross infection - epidemiology (114) 114
immunology (114) 114
chemotherapy (113) 113
anti-bacterial agents - pharmacology (110) 110
antifungal agents - therapeutic use (110) 110
cross infection - drug therapy (110) 110
infant, newborn (108) 108
medicine, general & internal (107) 107
staphylococcal infections - microbiology (106) 106
therapy (106) 106
bacteremia - prevention & control (105) 105
biofilms (101) 101
abridged index medicus (100) 100
nursing (99) 99
surgery (99) 99
medicine & public health (98) 98
cross infection - prevention & control (97) 97
intensive-care-unit (97) 97
blood (94) 94
patients (93) 93
cross infection (92) 92
biofilm (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1706) 1706
Spanish (50) 50
French (30) 30
German (11) 11
Turkish (9) 9
Japanese (7) 7
Italian (6) 6
Chinese (2) 2
Czech (2) 2
Danish (2) 2
Croatian (1) 1
Finnish (1) 1
Norwegian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Infectious Diseases, ISSN 0022-1899, 2014, Volume 210, Issue 9, pp. 1357 - 1366
Background. Limitations in treatment of biofilm-associated bacterial infections are often due to subpopulation of persistent bacteria (persisters) tolerant to... 
aminoglycoside | persister | catheter-related infections | biofilm | proton motive force | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | MANAGEMENT | TOLERANCE | SUSCEPTIBILITY | MICROBIOLOGY | IMMUNOLOGY | ANTIBIOTIC-LOCK THERAPY | GENTAMICIN | PSEUDOMONAS-AERUGINOSA | L-ARGININE | GROWTH | Escherichia coli Infections - prevention & control | Central Venous Catheters - microbiology | Escherichia coli - drug effects | Gentamicins - administration & dosage | Catheter-Related Infections - prevention & control | Pseudomonas Infections - prevention & control | Arginine - administration & dosage | Gentamicins - pharmacology | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Pseudomonas Infections - drug therapy | Rats | Central Venous Catheters - adverse effects | Pseudomonas aeruginosa - drug effects | Catheter-Related Infections - drug therapy | Drug Synergism | Animals | Arginine - pharmacology | Staphylococcal Infections - prevention & control | Anti-Bacterial Agents - pharmacology | In Vitro Techniques | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Aminoglycosides | Health aspects | Research | Index Medicus | Abridged Index Medicus | Biofilms/drug effects | Gentamicins/administration & dosage | Anti-Bacterial Agents/pharmacology | Staphylococcal Infections/drug therapy | Arginine/administration & dosage | Life Sciences | Escherichia coli Infections/drug therapy | Staphylococcus aureus/drug effects | Gentamicins/pharmacology | Catheter-Related Infections/prevention & control | Pseudomonas aeruginosa/drug effects | Staphylococcal Infections/prevention & control | Catheter-Related Infections/drug therapy | Central Venous Catheters/microbiology | Escherichia coli/drug effects | Bacteriology | Microbiology and Parasitology | Central Venous Catheters/adverse effects | Arginine/pharmacology | Pseudomonas Infections/prevention & control | Escherichia coli Infections/prevention & control | Pseudomonas Infections/drug therapy
Journal Article
Infection Control and Hospital Epidemiology, ISSN 0899-823X, 11/2016, Volume 37, Issue 11, pp. 1288 - 1301
Journal Article
European Journal of Clinical Microbiology & Infectious Diseases, ISSN 0934-9723, 9/2018, Volume 37, Issue 9, pp. 1627 - 1636
The proportion of antimicrobial resistance (AMR) among the ESKAPE and Escherichia coli (ESKAPEEc) pathogens causing bloodstream infection (BSI) increased... 
Medical Microbiology | Biomedicine | Targeted therapy | Escherichia coli | Bloodstream infections | Internal Medicine | ESKAPE | Antimicrobial resistance | MORTALITY | INFECTIOUS DISEASES | MULTICENTER | MICROBIOLOGY | THERAPY | PREDICTORS | DISSEMINATION | ENTEROBACTERIACEAE | PATHOGENS | Escherichia coli - drug effects | Humans | Escherichia coli Infections - blood | Molecular Targeted Therapy | Incidence | Bacteremia - microbiology | Hospitals, Teaching - statistics & numerical data | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Drug Resistance, Multiple, Bacterial | Staphylococcal Infections - microbiology | Catheter-Related Infections - epidemiology | Cross Infection - epidemiology | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Klebsiella Infections - drug therapy | Pseudomonas Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Bacteremia - drug therapy | Escherichia coli Infections - microbiology | beta-Lactamases - drug effects | Klebsiella Infections - microbiology | Pseudomonas Infections - microbiology | Cross Infection - drug therapy | Catheter-Related Infections - drug therapy | Bacterial Proteins - drug effects | Escherichia coli Infections - epidemiology | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Escherichia coli - genetics | Escherichia coli - isolation & purification | Catheter-Related Infections - microbiology | Cross Infection - microbiology | Bacteremia - epidemiology | Anti-Bacterial Agents - pharmacology | Drug resistance in microorganisms | Pneumonia | Bacterial pneumonia | Beta lactamases | Health aspects | Public health | Klebsiella | Health care | Pathogens | Communities | Carbapenemase | Antimicrobial agents | Infections | Drug resistance | Antiinfectives and antibacterials | Methicillin | E coli | Pseudomonas aeruginosa | Bacteria | Meropenem | Trends | Ciprofloxacin | Active control | Emergency medical services | Ceftazidime | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2009, Volume 48, Issue 2, pp. 203 - 212
Background. Catheter-related bloodstream infection (CRBSI) causes substantial morbidity and mortality, but few randomized, controlled studies have been... 
Control groups | Pathogens | Health outcomes | Microbiology | Mortality | Articles and Commentaries | Infections | Dosage | Catheters | Bacteremia | Blood | INFECTIOUS DISEASES | MULTICENTER | SAFETY | MICROBIOLOGY | IMMUNOLOGY | INTENSIVE-CARE UNIT | ATTRIBUTABLE MORTALITY | VANCOMYCIN | COSTS | BACTEREMIA | DOUBLE-BLIND | CRITICALLY-ILL PATIENTS | NOSOCOMIAL PNEUMONIA | Linezolid | Humans | Middle Aged | Cross Infection - mortality | Gram-Positive Bacterial Infections - mortality | Bacteremia - mortality | Male | Oxazolidinones - adverse effects | Skin Diseases, Bacterial - drug therapy | Oxazolidinones - therapeutic use | Anti-Bacterial Agents - therapeutic use | Acetamides - therapeutic use | Acetamides - adverse effects | Aged, 80 and over | Catheter-Related Infections - mortality | Adult | Female | Anti-Bacterial Agents - adverse effects | Bacteremia - drug therapy | Gram-Negative Bacterial Infections - drug therapy | Skin Diseases, Bacterial - mortality | Cross Infection - drug therapy | Catheter-Related Infections - drug therapy | Vancomycin - adverse effects | Vancomycin - therapeutic use | Adolescent | Aged | Gram-Positive Bacterial Infections - drug therapy | Gram-Negative Bacterial Infections - mortality | Infectious skin diseases | Blood-borne diseases | Care and treatment | Dosage and administration | Research | Antibiotics | Comparative studies | Skin | Drug therapy | Clinical outcomes | Index Medicus
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 13 - 32
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the... 
Hematologic malignancies | Invasive candidiasis | Medicine & Public Health | Hematology | Antifungal agents | Aspergillosis | Mycoses | Oncology | CHRONIC DISSEMINATED CANDIDIASIS | ACUTE MYELOID-LEUKEMIA | LIPOSOMAL AMPHOTERICIN-B | CLINICAL-PRACTICE GUIDELINES | HIGH-DOSE FLUCONAZOLE | DOUBLE-BLIND TRIAL | CENTRAL-NERVOUS-SYSTEM | OF-THE-LITERATURE | HEMATOLOGY | STEM-CELL TRANSPLANT | BLOOD-STREAM INFECTIONS | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Humans | Salvage Therapy | Catheter-Related Infections - prevention & control | Antifungal Agents - therapeutic use | Echinocandins - administration & dosage | Neoplasms - complications | Invasive Pulmonary Aspergillosis - etiology | Fungemia - drug therapy | Immunotherapy | Candidiasis, Invasive - drug therapy | Amphotericin B - administration & dosage | Mycoses - therapy | Drug Therapy, Combination | Candidiasis, Invasive - etiology | Triazoles - therapeutic use | Invasive Pulmonary Aspergillosis - drug therapy | Mycoses - surgery | Clinical Trials as Topic | Combined Modality Therapy | Chemotherapy-Induced Febrile Neutropenia - complications | Fungemia - prevention & control | Catheter-Related Infections - drug therapy | Amphotericin B - adverse effects | Echinocandins - adverse effects | Invasive Pulmonary Aspergillosis - surgery | Mycoses - drug therapy | Echinocandins - therapeutic use | Immunocompromised Host | Amphotericin B - therapeutic use | Drug Monitoring | Antifungal Agents - administration & dosage | Mycoses - etiology | Cancer patients | Care and treatment | Chemotherapy | Mortality | Clinical trials | Health aspects | Cancer | Index Medicus | Original
Journal Article
Burns, ISSN 0305-4179, 2016, Volume 43, Issue 3, pp. 642 - 653
Highlights • Burn depth/agent increases risk of developing an infection. • Infections found folliculitis, burn wound, urinary tract, pneumonia, CVC and... 
Critical Care | Nosocomial infection | Burn wound infection | Pneumonia | Urinary tract infection | Health care related infection | Burns | URINARY-TRACT-INFECTION | MORTALITY | SURGERY | RISK-FACTORS | DERMATOLOGY | REPLACEMENT | BACTERIOLOGY | CATHETERS | INTENSIVE-CARE-UNIT | SURVEILLANCE | ASSOCIATION | BLOOD-STREAM INFECTIONS | CRITICAL CARE MEDICINE | Escherichia coli | Humans | Middle Aged | Child, Preschool | Male | Young Adult | Folliculitis - epidemiology | Aged, 80 and over | Urinary Tract Infections - microbiology | Catheter-Related Infections - epidemiology | Child | Infant, Newborn | Staphylococcus aureus | Escherichia coli Infections - drug therapy | Bacteremia - drug therapy | Pseudomonas Infections - microbiology | Wound Infection - epidemiology | Catheter-Related Infections - drug therapy | Drug Resistance, Microbial | Escherichia coli Infections - epidemiology | Acinetobacter baumannii | Catheter-Related Infections - microbiology | Adolescent | Bacteremia - epidemiology | Infant | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Adult | Female | Pseudomonas aeruginosa | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Acinetobacter Infections - microbiology | Staphylococcal Infections - drug therapy | Colombia - epidemiology | Klebsiella Infections - drug therapy | Central Venous Catheters | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Folliculitis - microbiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Oxacillin - therapeutic use | Burns - epidemiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Wound Infection - microbiology | Aged | Folliculitis - drug therapy | Klebsiella pneumoniae | Development and progression | Burns and scalds | Surgery, Plastic | Health aspects | Staphylococcus aureus infections | Analysis | Bacterial pneumonia | Mortality | Urinary tract infections | Bacteria | Disease susceptibility | Antibacterial agents | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 09/2012, Volume 56, Issue 9, pp. 4738 - 4745
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
PATHOGENESIS | HOST DEFENSES | UROPLAKIN-IA | INTRACELLULAR BACTERIAL COMMUNITIES | STRUCTURAL BASIS | HISTOLOGICAL-CHANGES | PERSISTENCE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | BLADDER | FIMH | BIOFILM FORMATION | Molecular Weight | Biofilms - growth & development | Mannosides - therapeutic use | Adhesins, Escherichia coli - genetics | Uropathogenic Escherichia coli - pathogenicity | Gene Deletion | Female | Urinary Tract Infections - microbiology | Urinary Bladder - microbiology | Bacterial Adhesion - drug effects | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Mice, Inbred C57BL | Uropathogenic Escherichia coli - growth & development | Escherichia coli Infections - microbiology | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Cross Infection - drug therapy | Urinary Tract Infections - drug therapy | Catheter-Related Infections - drug therapy | Animals | Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology | Fimbriae Proteins - genetics | Uropathogenic Escherichia coli - drug effects | Catheter-Related Infections - microbiology | Cross Infection - microbiology | Urinary Catheters - microbiology | Mannosides - pharmacology | Urinary Bladder - drug effects | Mice | Fimbriae Proteins - deficiency | Index Medicus | Experimental Therapeutics
Journal Article
Journal Article
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 07/2017, Volume 12, Issue 7, pp. 1139 - 1146
Background and objectives Persons receiving outpatient hemodialysis are at risk for bloodstream and vascular access infections. The Centers for Disease Control... 
Infection | Surveillance | Dialysis | OUTPATIENT HEMODIALYSIS FACILITIES | RISK-FACTORS | ANTIMICROBIAL USE | RECOMMENDATIONS | BACTEREMIA | GUIDELINES | PREVENTION | UROLOGY & NEPHROLOGY | BLOOD-STREAM | INFECTION | VASCULAR ACCESS | Arteriovenous Shunt, Surgical - instrumentation | United States - epidemiology | Prognosis | Blood Vessel Prosthesis - adverse effects | Humans | Prosthesis-Related Infections - drug therapy | Bacteremia - microbiology | Blood Vessel Prosthesis Implantation - adverse effects | Prosthesis-Related Infections - microbiology | Time Factors | Catheter-Related Infections - diagnosis | Prosthesis-Related Infections - diagnosis | Staphylococcal Infections - microbiology | Methicillin Resistance | Catheter-Related Infections - epidemiology | Catheterization, Central Venous - adverse effects | Staphylococcal Infections - drug therapy | Prosthesis-Related Infections - epidemiology | Blood Vessel Prosthesis Implantation - instrumentation | Risk Factors | Quality Indicators, Health Care | Central Venous Catheters - adverse effects | Ambulatory Care | Catheter-Related Infections - drug therapy | Administration, Intravenous | Staphylococcal Infections - diagnosis | Anti-Infective Agents - administration & dosage | Staphylococcal Infections - epidemiology | Arteriovenous Shunt, Surgical - adverse effects | Catheter-Related Infections - microbiology | Renal Dialysis - adverse effects | Bacteremia - epidemiology | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Catheterization, Central Venous - instrumentation | Population Surveillance | Index Medicus | dialysis | infection | surveillance | Original
Journal Article
European Journal of Clinical Microbiology & Infectious Diseases, ISSN 0934-9723, 7/2017, Volume 36, Issue 7, pp. 1305 - 1315
We report our experience using the double-carbapenem combination as salvage therapy for patients with untreatable infections caused by KPC-2- producing... 
Internal Medicine | Medical Microbiology | Biomedicine | MORTALITY | RESISTANT | INFECTIOUS DISEASES | BETA-LACTAMASE | COLISTIN | REGIMEN | MICROBIOLOGY | SYNERGISTIC ACTIVITY | SEPSIS | Klebsiella pneumoniae - isolation & purification | Prospective Studies | Carbapenems - administration & dosage | Humans | Middle Aged | Male | Urinary Tract Infections - complications | Bacteremia - microbiology | Greece | Young Adult | Aged, 80 and over | Adult | Female | Urinary Tract Infections - microbiology | Klebsiella Infections - drug therapy | Thienamycins - administration & dosage | Bacteremia - drug therapy | Treatment Outcome | Klebsiella Infections - microbiology | beta-Lactamases - secretion | Urinary Tract Infections - drug therapy | Catheter-Related Infections - drug therapy | Catheter-Related Infections - microbiology | Adolescent | Klebsiella pneumoniae - enzymology | Aged | Anti-Bacterial Agents - administration & dosage | Salvage Therapy - methods | Care and treatment | Pneumonia | Bacterial pneumonia | Mortality | Beta lactam antibiotics | Septic shock | Urinary tract infections | Health aspects | Klebsiella | Therapy | Medical instruments | Antimicrobial agents | Infections | Urinary tract | Institutions | Patients | Ertapenem | Catheters | Bacteremia | Infusion | Salvage | Sepsis | Meropenem | Ventricle | Index Medicus
Journal Article